JP2003063969A - Functional goods using concentrated mineral solution obtained from deep sea water by separation - Google Patents

Functional goods using concentrated mineral solution obtained from deep sea water by separation

Info

Publication number
JP2003063969A
JP2003063969A JP2001254117A JP2001254117A JP2003063969A JP 2003063969 A JP2003063969 A JP 2003063969A JP 2001254117 A JP2001254117 A JP 2001254117A JP 2001254117 A JP2001254117 A JP 2001254117A JP 2003063969 A JP2003063969 A JP 2003063969A
Authority
JP
Japan
Prior art keywords
water
sea
mineral
concentrated
deep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001254117A
Other languages
Japanese (ja)
Other versions
JP2003063969A5 (en
Inventor
Akira Fujii
侃 藤井
Tetsuya Arai
哲也 荒井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goshu Yakuhin Co Ltd
Original Assignee
Goshu Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goshu Yakuhin Co Ltd filed Critical Goshu Yakuhin Co Ltd
Priority to JP2001254117A priority Critical patent/JP2003063969A/en
Publication of JP2003063969A publication Critical patent/JP2003063969A/en
Publication of JP2003063969A5 publication Critical patent/JP2003063969A5/ja
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide functional goods making use of functions which a concentrated mineral solution separated from cool water peculiar to the Sea of Japan has. SOLUTION: The functional goods using the concentrated mineral solution separated from cool water peculiar to the Sea of Japan particularly make use of a function for stabilizing the blood pressure, a function for improving allergic physical conditions and a function for improving lifestyle-related diseases, respectively or in combination, among the functions the concentrated mineral solution has.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】この発明は、海洋深層水より
分離したミネラル濃縮液の機能性を利用した商品に関す
るもので、具体的には機能性飲料、機能性食品、機能性
化粧品、機能性入浴剤等に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a product utilizing the functionality of a mineral concentrate separated from deep sea water, and specifically, functional drinks, functional foods, functional cosmetics, functional baths. Regarding agents, etc.

【0002】[0002]

【従来の技術】海洋深層水は海面下300m以下にあっ
て高水圧下を受けているため、総ての元素が長期間に渡
り溶け込み、生体保持に必要な無機栄養塩類に富み、有
機物や細菌類が少なく清浄性があって、年間を通じて低
温で安定していることが知られている。また深層水のミ
ネラル分は、表層水より多いことも知られている。特
に、日本海側の特異な立地条件下にある富山湾の海洋深
層水(以下、日本海固有冷水とする)については様々な
研究が行われ、その研究から独自の特徴を有することが
逐次解明されていると共に、その特徴を利用した発明も
出願されている。
2. Description of the Related Art Deep sea water is under 300 m below sea level and is subject to high water pressure. Therefore, all elements are dissolved for a long period of time, rich in inorganic nutrients necessary for living body support, organic substances and bacteria. It is known to have few kinds and cleanliness and to be stable at low temperatures throughout the year. It is also known that the mineral content of deep water is higher than that of surface water. In particular, various studies have been conducted on the deep sea water of Toyama Bay (hereinafter referred to as "cool water peculiar to the Sea of Japan"), which is under unique location conditions on the Sea of Japan side. In addition to the above, an invention utilizing the feature has been filed.

【0003】一方、海水から塩を得る手段として、逆浸
透膜法やイオン交換膜法が用いられている。イオン交換
膜法は、陽イオン交換膜(陽イオンのみを通す膜)を利
用し、食塩水の電解から水酸化ナトリウムや塩素ガスを
得る方法として確立しており、その応用として、陽イオ
ン交換膜と陰イオン交換膜とを交互に配置した多槽の電
解槽で食塩水を電気分解すると、中間槽において電気透
析が起こり、交互の槽に原液より濃い食塩水と薄い食塩
水が得られる。この方式によれば食塩水を薄くできるた
め、海水から飲料水を得る淡水化プラントとして用いら
れている。
On the other hand, the reverse osmosis membrane method and the ion exchange membrane method are used as means for obtaining salt from seawater. The ion exchange membrane method has been established as a method of obtaining sodium hydroxide and chlorine gas from electrolysis of saline solution by using a cation exchange membrane (a membrane that allows only cations to pass through). When the saline solution is electrolyzed in a multi-tank electrolytic cell in which the and anion exchange membranes are alternately arranged, electrodialysis occurs in the intermediate tank, and a salt solution thicker than the stock solution and a thin saline solution are obtained in the alternate tanks. According to this method, the salt solution can be thinned, and thus it is used as a desalination plant for obtaining drinking water from seawater.

【0004】[0004]

【発明が解決しようとする課題】逆浸透膜を用いた淡水
化手段において、成分比率の圧倒的に多い塩素(Cl)
とナトリウム(Na)を分離除去すると、塩素及びナト
リウムの分離と略同率で他の有用ミネラル分も除去され
るため、海水と分離後の淡水とにおけるミネラル分の含
有率に変化は少なく、故に、淡水における有用ミネラル
分の残存が乏しくなる問題点があった。、
DISCLOSURE OF THE INVENTION In a desalination means using a reverse osmosis membrane, chlorine (Cl) having an overwhelmingly large component ratio is used.
And sodium (Na) are separated and removed, other useful minerals are also removed at about the same rate as the separation of chlorine and sodium, so there is little change in the content of minerals in seawater and fresh water after separation. There is a problem that useful minerals in fresh water are scarcely left. ,

【0005】深層水の有用ミネラル分は表層水より多い
が、それでもNa、Clの1%未満しか含有していな
い。故に、深層水を濾過するだけでは、NaとCl、及
びミネラル分の含有率に変化がない。従ってろ過や逆浸
透膜によって分離した淡水のミネラル分は無きに等しい
ので、これらを栄養補給等の目的に用いても、ミネラル
分を補給することができない問題点もあった。
The useful mineral content of deep water is higher than that of surface water, but it still contains less than 1% of Na and Cl. Therefore, the filtration of deep water does not change the Na and Cl and mineral content. Therefore, since the mineral content of fresh water separated by filtration or the reverse osmosis membrane is inevitably equal, there is a problem that the mineral content cannot be replenished even if these are used for the purpose of nutritional supplementation.

【0006】そこでこの発明は、日本海固有冷水から有
用ミネラル成分を選択分離する技術の研究を進めると共
に、分離したミネラル濃縮液の機能性を追及し、独自の
機能性を有することを付きとめ、その有用性を利用した
機能性商品を提供することに成功したものである。
Therefore, the present invention advances the research on the technology for selectively separating useful mineral components from cold water peculiar to the Sea of Japan, and pursues the functionality of the separated mineral concentrated liquid, and finds that it has unique functionality, We have succeeded in providing functional products that make use of their usefulness.

【0007】[0007]

【課題を解決するための手段】上記目的を達成するため
に、本発明の日本海固有冷水より分離したミネラル濃縮
液を用いた機能性商品は、ミネラル濃縮液が保持する機
能性の内、特に血圧の安定に寄与する機能性、アレルギ
ー体質の改善機能性、生活習慣病の改善に寄与する機能
性等を個別に利用したり、或はそれらの機能を併用して
利用し得るようにしたものである。
In order to achieve the above-mentioned object, a functional product using a mineral concentrate separated from cold water peculiar to the Sea of Japan of the present invention is Functionality that contributes to stability of blood pressure, improvement functionality of allergic constitution, functionality that contributes to improvement of lifestyle-related diseases, etc., or those functions can be used in combination Is.

【0008】ここで日本海固有冷水とは、日本海最大の
外洋性内湾である富山湾(広さ2120km2、湾の中
央付近が水深さ1000m以上に達し、しかも3000
m級の山々から1年を通じて雪解け水が流れ込み、岸が
深い上、急勾配であり、大陸棚の発達が乏しく、海底に
は「おぼれ谷」と呼ばれる海谷がいくつも存在し、深海
に生息する蛍イカ、白エビ、バイ貝の生息地として有名
であり、且つ蜃気楼が発生するという特異な特徴があ
る)の深層水を言い、河川水等の陸水の影響を受けた塩
分の低い沿岸表層水、その下層に200〜300mの厚
みを持つ対馬暖流系水、そして300m以深に位置して
いる。
[0008] Here, the cold water peculiar to the Sea of Japan means Toyama Bay (area 2120 km2, the depth near the center of the bay reaches 1,000 m or more, and is 3000, which is the largest open sea inland bay of the Sea of Japan.
Melting water flows from the m-class mountains throughout the year, the shore is deep and the slope is steep, the continental shelf is poorly developed, and there are many sea valleys called "Obore Valley" on the seabed, which live in the deep sea. Famous as a habitat for firefly squid, white shrimp, and shellfish, and has a unique feature that mirages occur.) It refers to the deep water, and the coastal surface layer with low salinity that is affected by inland water such as river water. Water, Tsushima warm current water with a thickness of 200-300m below it, and deeper than 300m.

【0009】日本海固有冷水は、富山湾の容積の約65
%を占めており、特開2000−290168号、特開
2000−290161号等に記載した通り、高知県の
外洋深層水と若干異なり、その性状として、年間を通じ
て2℃以下の低温で水温変化がほとんどなく、塩分(3
4.0〜34.1psu)も安定しており、表層水と比
較して栄養塩類が著しく豊富に含まれ、有機物や細菌類
が非常に少ないという特徴が挙げられる。
The cold water peculiar to the Sea of Japan is about 65 times the volume of Toyama Bay.
%, And as described in JP 2000-290168 A, JP 2000-290161 A, etc., is slightly different from the deep sea water of Kochi prefecture, and as a property thereof, the water temperature changes at a low temperature of 2 ° C. or less throughout the year. Almost no salt (3
It is also stable at 4.0 to 34.1 psu), has a remarkably rich amount of nutrient salts compared to surface water, and has very few organic substances and bacteria.

【0010】(1)日本海固有冷水は高知県室戸岬の北
太平洋深層水と比べて溶存酸素量が多く、深層水として
の年齢が若いことを示している。 (2)両深層水を表層水と比較すると、日本海固有冷水
の方がリン酸態リン、硝酸態窒素などの無機栄養塩類が
多く、且つ一般生菌数が少なかった。このことは、日本
海固有冷水の水温が高知県室戸岬の北太平洋深層水に比
べて約5℃も低いことによるものと思われる。 (3)日本海固有冷水の生菌数、及び真菌数は、表層水
よりかなり少なかった。
(1) The cold water peculiar to the Sea of Japan has a large amount of dissolved oxygen as compared with the deep water in the North Pacific Ocean at Cape Muroto in Kochi Prefecture, indicating that it is young as deep water. (2) Comparing both deep water and surface water, cold water peculiar to the Sea of Japan contained more inorganic nutrients such as phosphate phosphorus and nitrate nitrogen, and the number of general viable bacteria was smaller. This seems to be because the temperature of the cold water peculiar to the Sea of Japan is about 5 ° C lower than the deep water in the North Pacific Ocean at Cape Muroto, Kochi Prefecture. (3) The number of viable bacteria and fungi in the cold water peculiar to the Sea of Japan was considerably smaller than that in surface water.

【0011】ここでミネラル濃縮液とは、一次電気透析
装置にて日本海固有冷水を分離し、日本海固有冷水から
淡水を取り除いて得た濃縮深層水を、更に二次電気透析
装置により分離し、濃縮深層水から濃縮塩水を取り除
き、有用ミネラルを選択して濃縮したものであり、特に
生体適合成分を混在しているものを言い、液状、粉状を
成しており、そのまま利用し得る勿論、自由な濃度に希
釈して用いることのできるものを言う。ここで機能性と
は、例えば血圧の安定、アレルギー体質の改善、生活習
慣病の改善等に対して特定の効果が期待できるもの、特
定の効果を発揮するもの等を言う。
Here, the mineral concentrate is obtained by separating the cold water characteristic of the Sea of Japan with a primary electrodialyzer and removing concentrated fresh water from the cold water characteristic of the Sea of Japan to further separate the concentrated deep water with a secondary electrodialyzer. , Concentrated salt water is removed from concentrated deep water, and useful minerals are selected and concentrated. Especially, it means that biocompatible components are mixed, and it is in liquid or powder form and can be used as it is. , That can be used after diluting to a free concentration. Here, the term "functionality" refers to, for example, a compound that can be expected to have a specific effect, a compound that exhibits a specific effect, or the like with respect to stability of blood pressure, improvement of allergic constitution, improvement of lifestyle-related diseases and the like.

【0012】[0012]

【発明の実施形態】本発明の日本海固有冷水より分離し
たミネラル濃縮液を用いた機能性商品について説明する
と、ミネラル濃縮液が保持するの機能性の内、特に血圧
の安定に寄与する機能性、アレルギー体質の改善に寄与
する機能性、生活習慣病の改善に寄与する機能性等を個
別に利用したたもの、及びそれらの機能性を併用して利
用し得るようにしたものである。
BEST MODE FOR CARRYING OUT THE INVENTION A functional product using a mineral concentrate separated from cold water peculiar to the sea of the present invention will be described. Among the functions of the mineral concentrate, the functionality that contributes particularly to the stabilization of blood pressure. , A function that contributes to the improvement of allergic constitution, a function that contributes to the improvement of lifestyle-related diseases, and the like, and those that can be used in combination.

【0013】ミネラル濃縮液は図1の如く、一次電気透
析装置1と、二次電気透析装置2とから成る多段式電気
透析システムにて分離するもので、一次電気透析装置1
はイオン交換膜11を備え、日本海固有冷水Aを淡水B
(塩分を取り除い)と、濃縮深層水C(水分を取り除い
た)とに分離し、二次電気透析装置2は一価イオン選択
性に優れたイオン交換膜12を備え、一次電気透析装置
1にて分離した濃縮深層水Cを更に分離し、濃縮深層水
Cから一価の元素類を主成分とする濃縮塩水Eを取り除
いて得たものである。
As shown in FIG. 1, the mineral concentrate is separated by a multi-stage electrodialysis system consisting of a primary electrodialysis device 1 and a secondary electrodialysis device 2.
Is equipped with an ion-exchange membrane 11, and the cold water A unique to the Sea of Japan
(The salt is removed) and the concentrated deep-water C (water is removed) are separated, and the secondary electrodialysis device 2 is provided with the ion exchange membrane 12 having excellent monovalent ion selectivity. It is obtained by further separating the concentrated deep-layer water C separated as described above, and removing the concentrated salt water E containing monovalent elements as a main component from the concentrated deep-layer water C.

【0014】一次電気透析装置1は、日本海固有冷水A
を淡水Bと濃縮深層水Cとに分離し、二次電気透析装置
2は濃縮深層水Cをミネラル濃縮液Dと濃縮塩水Eとに
分離し、本発明商品に用いる一価のプラス元素とマイナ
ス元素とを除去したミネラル濃縮液Dを得る。ミネラル
濃縮液Dの分離において、イオン交換膜11,12によ
り過剰成分を分離する方法(人体に有用と思われるミネ
ラル分の採取と、人体に有害と思われる極微量成分の除
去を可能にした透析膜)を検討した。即ち、数種類のイ
オン交換膜11,12を用いて日本海固有冷水Aを処理
し、その処理液の成分分析を行うことにより適切なイオ
ン交換膜11,12を選定した。
The primary electrodialysis device 1 is a cold water A unique to the Sea of Japan.
Is separated into fresh water B and concentrated deep water C, and the secondary electrodialyzer 2 separates concentrated deep water C into mineral concentrated liquid D and concentrated salt water E, and a monovalent plus element and a minus used for the product of the present invention. A mineral concentrate D from which elements and are removed is obtained. In the separation of the mineral concentrate D, a method of separating excess components by the ion-exchange membranes 11 and 12 (dialysis that enables the collection of minerals that are considered to be useful to the human body and the removal of trace amounts of components that are considered to be harmful to the human body) Membrane). That is, the cold water A specific to the Sea of Japan was treated using several kinds of ion exchange membranes 11 and 12, and the appropriate ion exchange membranes 11 and 12 were selected by analyzing the components of the treated liquid.

【0015】本発明の機能性商品は、各種商品にミネラ
ル濃縮液Dを付加したものであり、代表的な用途とし
て、図2の如く血圧の安定化を願う商品群、アレルギー
体質の改善を願う商品群、生活習慣病の改善を願う商品
群が上げられる。図2において、海洋深層水は日本海固
有冷水Aを表し、ミネラルはミネラル濃縮液Dを表す。
また、還元水の欄は、深層水と還元水の性質が同等と言
われていることに由来する。
The functional product of the present invention is a product in which the mineral concentrate D is added to various products. As typical applications, as shown in FIG. 2, a product group for which blood pressure is stabilized and an allergic constitution is desired to be improved. The product group and the product group wishing to improve lifestyle-related diseases are listed. In FIG. 2, deep sea water represents the unique cold water A of the Sea of Japan, and minerals represent the mineral concentrate D.
The column of reduced water is derived from the fact that the properties of deep water and reduced water are said to be equivalent.

【0016】本発明による機能性商品の具体的な用途と
して、図3の如くミネラルウォーター、清涼飲料、果実
飲料、スポーツドリンク、乳清飲料、入浴剤、医薬品、
医薬部外品、口内洗浄液、鼻腔洗浄液、化粧品類、毛髪
用品、加工食品、栄養補助品、特殊用途向け食品、菓
子、パン、調味料、食品添加物等の他に、酒類(例えば
ビール、日本酒、洋酒、果実酒、中国酒、薬味酒)にも
用いることができる。
Specific applications of the functional product according to the present invention include mineral water, soft drinks, fruit drinks, sports drinks, whey drinks, bath salts, pharmaceuticals, as shown in FIG.
In addition to quasi-drugs, mouthwash, nasal cavity wash, cosmetics, hair products, processed foods, nutritional supplements, special-purpose foods, confectionery, bread, seasonings, food additives, etc., liquors (eg beer, sake) , Western liquor, fruit liquor, Chinese liquor, condiment liquor).

【0017】[0017]

【実験例1】ミネラル濃縮液のL−NAME誘発高血圧
ラットに及ぼす影響を、図4の試験方法を用いて実験し
た。この実験に用いたNO合成阻害薬、L−NAMEの
血圧上昇メカニズムは図5の通りである。上記試験にお
いて、L−NAME誘発高血圧ラットにおける体重推移
に及ぼす影響を測定した所、図6の如く結果が得られ、
これを図7に図表化した。L−NAME誘発高血圧ラッ
トにおける血圧に及ぼす影響を測定した所、図8の如く
結果が得られ、これを図9に図表化した。L−NAME
誘発高血圧ラットにおける心拍数に及ぼす影響を測定し
た所、図10の如く結果が得られた。尚、図4〜10に
おける深層水は、日本海固有冷水Aより分離したミネラ
ル濃縮液Dを指す。
[Experimental Example 1] The effect of a mineral concentrate on L-NAME-induced hypertensive rats was tested using the test method shown in FIG. The blood pressure elevation mechanism of L-NAME, an NO synthesis inhibitor used in this experiment, is as shown in FIG. In the above test, when the effect on the body weight transition in L-NAME-induced hypertensive rats was measured, the results shown in FIG. 6 were obtained,
This is illustrated in FIG. When the effect on blood pressure in L-NAME-induced hypertensive rats was measured, the results shown in FIG. 8 were obtained, and the results are shown in FIG. L-NAME
When the effect on the heart rate in induced hypertensive rats was measured, the results were obtained as shown in FIG. The deep water in FIGS. 4 to 10 indicates the mineral concentrate D separated from the cold water A peculiar to the Sea of Japan.

【0018】L−NAME誘発高血圧ラットにおける血
流量に及ぼす影響 方法、雄性SD系ラットをペントパルビタール.ネトリ
ウム(30−40mg/kg、腹腔内投与)により麻酔
し、背位に固定後、頚部を正中線に沿って切開する。左
総頚動脈を周囲の結合組織より剥離してflow probe(プ
ライムテック、HDP20.20R:φ20mm)を装
着し、パルスドップラー血流針(クリスタルバイオテッ
ク、PD−20)を用いて血流を測定し、LINEAC
ORDER(グラフテック、WR3101)上に記録す
る。測定はチャート上に数分間記録した後、比較的安定
した所を読み取り血流量とする。結果は図11に(平均
値±標準誤差で)示し、統計解析は一元配置分析により
行う。
Effect on blood flow in L-NAME-induced hypertensive rats Method: Male SD rats were anesthetized with pentoparbital.nettrium (30-40 mg / kg, intraperitoneal administration) and fixed in the dorsal position, then the neck was fixed. Make an incision along the midline. The left common carotid artery is detached from the surrounding connective tissue, a flow probe (Primetech, HDP20.20R: φ20 mm) is attached, and blood flow is measured using a pulse Doppler blood flow needle (Crystal Biotech, PD-20). , LINEAC
Record on ORDER (Graphtech, WR3101). The measurement is recorded on the chart for several minutes, and then the relatively stable place is read and used as the blood flow rate. The results are shown in FIG. 11 (mean value ± standard error), and statistical analysis is performed by one-way analysis.

【0019】[0019]

【実験例2】ミネラル濃縮液のマウスIgE抗体生産に
及ぼす影響を、図12の試験方法を用いて実験した。こ
の実験に用いたマウスIgE(免疫グロブリンE)抗体
生産の特徴は図13の通りである。上記試験におけるI
gE抗体価測定は図14の通りであり、ミネラル濃縮液
のマウスIgE抗体生産に及ぼす影響は図15の如くで
あった。 a、体重の推移 ミネラル濃縮液のマウスIgE抗体生産における体重の
推移を測定した所、図16の如く結果が得られ、これを
図17に図表化した。対照群、及び水道水投与群におけ
る体重増加推移は、両群とも経日的に増加した。一方、
ミネラル濃縮液投与群の体重増加推移は、対照群、及び
水道水投与群のそれと比較して低値を示したが、核群間
に有意な差は認められなかった。 b、IgE抗体生産に対する作用 対照群のIgE抗体は、9・0±00・55(log
2:512)であった。水道水投与群では8・83±0
・79の抗体価を示した。一方、ミネラル濃縮液投与群
のIgE抗体は、8・33±0・61を示し、対照群、
及び水道水投与群のそれと比較してIgE抗体生産を抑
制させる傾向を示した。非感作群(正常群)では、卵白
アルブミンに対するIgE抗体の生産は診とめられなか
った。尚、図13〜17における深層水は、日本海固有
冷水Aより分離したミネラル濃縮液Dを指す。
[Experimental Example 2] The effect of a mineral concentrate on mouse IgE antibody production was tested using the test method shown in FIG. The characteristics of mouse IgE (immunoglobulin E) antibody production used in this experiment are shown in FIG. I in the above test
The gE antibody titer measurement was as shown in FIG. 14, and the influence of the mineral concentrate on mouse IgE antibody production was as shown in FIG. a. Transition of body weight When the transition of body weight in mouse IgE antibody production of the concentrated mineral solution was measured, the results were obtained as shown in FIG. 16, which is shown in FIG. The changes in body weight in the control group and the tap water-administered group increased with time in both groups. on the other hand,
The change in body weight of the mineral concentrate administration group was lower than those of the control group and the tap water administration group, but no significant difference was observed between the nuclear groups. b, Effect on IgE antibody production IgE antibody in the control group was 9.0 ± 00.55 (log
2: 512). 8.83 ± 0 in the tap water administration group
-An antibody titer of 79 was shown. On the other hand, the IgE antibody of the mineral concentrate administration group showed 8.33 ± 0.61, which was
And showed a tendency to suppress IgE antibody production as compared with that of the tap water administration group. In the non-sensitized group (normal group), production of IgE antibody against ovalbumin was not detected. The deep water in FIGS. 13 to 17 indicates the mineral concentrate D separated from the cold water A peculiar to the Sea of Japan.

【0020】[0020]

【実験例3】ミネラル濃縮液の実験的生活習慣病モデル
に及ぼす影響を、図18の試験方法を用いて実験した。
この実験に用いた実験的生活習慣病モデルは図19の通
りである。上記試験において、生活習慣病モデルにおけ
るミネラル濃縮液の体重に及ぼす影響を測定した所、図
20の如く結果が得られたし、生活習慣病モデルにおけ
るミネラル濃縮液の血糖に及ぼす影響を測定した所、図
21の如く結果が得られた。また、生活習慣病モデルに
おける総コレストロールに及ぼす影響を測定した所、図
22の如く結果が得られたし、生活習慣病モデルにおけ
るトリグリセリドに及ぼす影響を測定した所、図23の
如く結果が得られた。更に、生活習慣病モデルにおける
血小板凝集能に及ぼす影響を測定した所、図24の如く
結果が得られた。尚、図18〜24における深層水は、
日本海固有冷水Aより分離したミネラル濃縮液を指す。
[Experimental Example 3] The effect of the mineral concentrate on the experimental lifestyle-related disease model was tested using the test method shown in FIG.
The experimental lifestyle-related disease model used in this experiment is as shown in FIG. In the above test, the effect of the mineral concentrate on the body weight was measured in the lifestyle-related disease model, the results were obtained as shown in FIG. 20, and the effect of the mineral concentrate on the blood glucose in the lifestyle-related disease model was measured. The results were obtained as shown in FIG. In addition, when the effect on total cholesterol in the lifestyle-related disease model was measured, the results were obtained as shown in FIG. 22, and when the effect on triglyceride in the lifestyle-related disease model was measured, the results were obtained as shown in FIG. It was Further, when the influence on the platelet aggregation ability in the lifestyle-related disease model was measured, the results were obtained as shown in FIG. The deep water in FIGS.
A mineral concentrate separated from the cold water A peculiar to the Sea of Japan.

【0021】[0021]

【実施例】日本海固有冷水Aと、該日本海固有冷水Aか
ら分離した淡水B、ミネラル濃縮液D、濃縮塩水Eの成
分は図25の通りであった。また日本海固有冷水Aより
分離した淡水Bと濃縮深層水C、及び濃縮深層水Cより
分離したミネラル濃縮液Dと濃縮塩水Eのイオン含有量
は図26の通りであった。このことから、淡水Bを例え
ばミネラル濃縮液Dや濃縮塩水Eの希釈に用いることも
可能であるし、濃縮塩水Eを充填物の殺菌手段や滅菌手
段等として用いることも可能である。尚、図25におけ
る原水は日本海固有冷水Aを指し、濃塩水は濃縮塩水E
を指す。
EXAMPLE The components of the cold water A peculiar to the Sea of Japan, the fresh water B separated from the cold water A peculiar to the Sea of Japan, the mineral concentrated liquid D, and the concentrated salt water E were as shown in FIG. The ion contents of the fresh water B and concentrated deep water C separated from the cold water A unique to the Sea of Japan, and the mineral concentrated liquid D and concentrated salt water E separated from the concentrated deep water C are as shown in FIG. Therefore, the fresh water B can be used for diluting the mineral concentrated liquid D or the concentrated salt water E, for example, or the concentrated salt water E can be used as a sterilizing means or a sterilizing means of the filling material. The raw water in FIG. 25 indicates the cold water A peculiar to the Sea of Japan, and the concentrated salt water is the concentrated salt water E.
Refers to.

【0022】ミネラル濃縮液Dとして、体液に近い生体
適合成分の塩素イオン、窒素イオン、ヨウ素イオン、ナ
トリウム、マグネシウム、カリウム、カルシウム、スト
ロンチウム、リチウム、ルビジウム、カドミウム、バリ
ウム、バナジウム、アルミニウム、ゲルマニウム、モリ
ブテン、ホウ素、溶性珪素、全リン、亜鉛、ヒ素、銅、
鉛、鉄、ニッケル、クロム、マンガン、セレン、コバル
ト等を残すことが望ましい。淡水Bは塩化ナトリウムや
塩素等を除いた脱塩水であり、濃縮深層水Cは水分を飛
ばして濃縮したもので、水分を完全に飛ばして粉状に濃
縮したものも含まれる。
As the mineral concentrate D, chlorine ions, nitrogen ions, iodine ions, sodium, magnesium, potassium, calcium, strontium, lithium, rubidium, cadmium, barium, vanadium, aluminum, germanium, molybdenum which are biocompatible components close to body fluids. , Boron, soluble silicon, total phosphorus, zinc, arsenic, copper,
It is desirable to leave lead, iron, nickel, chromium, manganese, selenium, cobalt, etc. The fresh water B is demineralized water from which sodium chloride, chlorine, etc. have been removed, and the concentrated deep-layer water C is one in which water has been removed and concentrated, and one in which water has been completely removed and powdered is also included.

【0023】ミネラル濃縮液Dの成分は、性質の異なる
イオン交換膜11,12を組み合わせることにより、更
に細かく分離することも可能であるので、本発明の実験
で得た機能性以外の機能性も期待できる。ミネラル濃縮
液Dの商品への含有範囲は、商品の種類によっても異な
るが、一般的に50%以下、望ましい範囲は25%以
下、最適な範囲は10%以下である。ミネラル濃縮液D
と濃縮塩水Eとの各元素濃度を比較した所、効率よく一
価イオンの除去が行われていること、及び微量金属元素
の濃縮が行われていることが確認された。味覚とミネラ
ル含有量とは相反する要素であるが、人それぞれの体質
に適したミネラル含有量と味覚を選択できる。
The components of the mineral concentrate D can be separated into finer particles by combining the ion-exchange membranes 11 and 12 having different properties, so that the functionalities other than those obtained in the experiment of the present invention can be obtained. Can be expected. The content range of the mineral concentrate D in the product varies depending on the type of the product, but is generally 50% or less, the desirable range is 25% or less, and the optimum range is 10% or less. Mineral concentrate D
As a result of comparing the element concentrations of the concentrated salt water E and the concentrated salt water E, it was confirmed that the monovalent ions were efficiently removed and that the trace metal elements were concentrated. Although the taste and the mineral content are contradictory factors, it is possible to select the mineral content and taste suitable for each person's constitution.

【0024】[0024]

【発明の効果】本発明のミネラル濃縮液を利用した機能
性商品は上記のとおりであるから、次に記載する効果を
奏する。高付加価値のある海洋深層水商品、或いは栄養
バランスのある海洋深層水商品を提供し得る。他種類の
ミネラルを含有するので、これを飲料類や食品類に用い
ると栄養バランスが向上し、無機栄養塩類の含有率が高
まり、その分のミネラルの添加を省略し得る。
The functional products using the mineral concentrate of the present invention are as described above, and therefore have the following effects. It is possible to provide high-value-added deep sea water products or nutritionally balanced deep sea water products. Since it contains other kinds of minerals, when it is used in beverages and foods, the nutritional balance is improved, the content rate of inorganic nutrient salts is increased, and the addition of minerals in that amount can be omitted.

【0025】イオン交換膜の選択により、人体に有用と
思われるミネラル分を漏れなく採取し、極微量の有害と
思われる成分を除去し、即ち、体液に近いミネラル成分
のみを残すことが可能となるので、塩分が少ないので、
塩分による刺激を少なくし、体質にやさしい海商品を提
供することができる。ミネラル濃縮液に電気透析処理し
た淡水(脱塩水)を混合することにより、100天然海
洋深層水より生成した、ミネラル含有量の高い飲料の提
供が可能となる。
By selecting the ion-exchange membrane, it is possible to collect all the minerals that are considered to be useful to the human body without leakage, and to remove the trace amount of harmful components, that is, to leave only the mineral components close to body fluid. As it has a low salt content,
It is possible to provide sea products that are mild to the constitution by reducing the irritation caused by salt. By mixing electrolyzed fresh water (demineralized water) with the mineral concentrate, it is possible to provide a beverage having a high mineral content, which is produced from 100 natural deep sea water.

【0026】L−NAME誘発高血圧ラットに対する効
果を要約すると、図27(図の深層水はミネラル濃縮液
を指す)の如く体重の推移に対しては、体重増加の抑制
傾向を示し、血圧に対しては、L−NAME負荷による
約30mmHgの上昇を抑制させる傾向を示し、心拍数
に対しては、L−NAME負荷による低下(5週目;7
0beats/min)をやや増強させ、血流量に対し
ては、L−NAME負荷による減少を増加ささせる傾向
を示した。
To summarize the effects on L-NAME-induced hypertensive rats, as shown in FIG. 27 (deep water in the figure indicates a mineral concentrate), there is a tendency to suppress weight gain with respect to the change in body weight, and to blood pressure. Shows a tendency to suppress an increase of about 30 mmHg due to L-NAME loading, and a decrease in L-NAME loading due to L-NAME loading (5th week; 7
0 beats / min) was slightly enhanced, and the blood flow showed a tendency to increase the decrease due to L-NAME loading.

【0027】マウスのIgE抗体生産に対する効果を要
約すると、マウスIgE抗体生産に対し卵白アルブミン
に対するIgE抗体生産を抑制させる傾向を示すので、
図28の如く関係にあると推察されるし、生活習慣病モ
デルラットに対する効果を要約すると、図29の如く関
係にあると推察される。試験結果を、L−NAME誘発
高血圧ラットとマウスIgE抗体生産と生活習慣病モデ
ルラットにおいてまとめると、図30の如くなる。図2
7〜30における深層水は、日本海固有冷水Aより分離
したミネラル濃縮液を指す。
To summarize the effect on mouse IgE antibody production, it shows a tendency to suppress IgE antibody production against ovalbumin against mouse IgE antibody production.
It is inferred that there is a relationship as shown in FIG. 28, and the effects on the lifestyle-related disease model rat are summarized as shown in FIG. 29. The test results are summarized in FIG. 30 when L-NAME-induced hypertensive rats and mouse IgE antibody production and model rats for lifestyle-related diseases are summarized. Figure 2
Deep water in 7 to 30 refers to a mineral concentrate separated from the cold water A peculiar to the Sea of Japan.

【0028】日本海固有冷水のミネラル濃縮液は、脳梗
塞、心筋梗塞、肩こり、便秘の改善に役立ち、還元水と
して、糖尿病、動脈硬化、アレルギーの改善に役立つと
推察できる。緻密なイオン交換膜を使用することで、適
度なミネラル成分を含んでいるので、付加価値を高めた
商品の製造に貢献する。
It can be presumed that the mineral concentrate of the cold water unique to the Sea of Japan is useful for improving cerebral infarction, myocardial infarction, stiff shoulder and constipation, and as reducing water, it is useful for improving diabetes, arteriosclerosis and allergies. By using a dense ion exchange membrane, it contains appropriate mineral components, which contributes to the production of products with increased added value.

【0029】化粧品としての機能性(優位性)について
検討すると、例えば、海水のミネラルバランスより塩化
ナトリウム分を減少し、人間の体液や羊水に近い成分に
すれば、肌の形成過程で免疫性がない胎児の皮膚形成、
保護に深く関わりを持つ商品、肌のバリア性を形成する
商品を提供できる。即ち、頭髪の性質に応じた商品、皮
膚の機能回復に有効な化粧品、また、皮膚に優しい化粧
品原料として付加価値性の高いものが製造可能となる。
Examining the functionality (predominance) of cosmetics, for example, if the sodium chloride content is reduced from the mineral balance of seawater to make it a component close to human body fluid or amniotic fluid, immunity will be increased during the skin formation process. No fetal skin formation,
It is possible to provide products that are deeply involved in protection and products that form barrier properties for the skin. In other words, it is possible to manufacture products that are suitable for the properties of hair, cosmetics that are effective in recovering the functions of the skin, and products that are highly value-added as skin-friendly cosmetic raw materials.

【0030】入浴剤としての機能性(優位性)について
検討すると、保湿性が高く、且つ刺激性の低い、全身の
皮膚疾患へも有用な肌に優しい入浴剤の商品化を可能と
する。ミネラル濃縮液を使用することで、羊水の再現が
可能となり、皮膚の弱い子供向け(アトピー性皮膚炎
等)に有用な入浴剤の開発が可能となる。
Examining the functionality (dominance) as a bath agent, it is possible to commercialize a skin-friendly bath agent having high moisturizing properties and low irritation, which is useful for general skin diseases. By using the mineral concentrate, it is possible to reproduce amniotic fluid and to develop a bath salt useful for children with weak skin (atopic dermatitis, etc.).

【0031】飲料に用いる場合、味覚とミネラル含有量
とは相反する要素であるが、人それぞれの体質に適した
ミネラル含有量と味覚を選択できる幅を広めた商品が可
能となる。また、体液と海水のミネラル含有量の違いと
して、CaとMgの含有順位が逆転しているが、この差
を埋めるべく大地のミネラルウォーター成分をミックス
させることでバランス的にも整合が図れる。硬度が必要
以上に高すぎる場合、下痢をする者も多く、また味覚的
にも重く苦味も増す。そこで、おいしさと、お腹へのや
さしさがバランスした硬度として、200〜250に設
定することが好ましい。また、同硬度の他商品に比べ、
塩素イオン、ナトリウムイオン、カリウムイオンを適度
に除去しているため、非常に飲みやすく、且つ体に優し
い商品となる。濃縮深層水を一価イオン選択性に優れた
イオン交換膜を用いた電気透析装置により分離し、一価
の元素類を取り除いたミネラル成分を得た。
When used in beverages, the taste and the mineral content are contradictory factors, but a product having a wide range of choices of the mineral content and taste suitable for each person's constitution becomes possible. In addition, as the difference in mineral content between body fluid and seawater, the order of Ca and Mg content is reversed, but by matching the mineral water components of the ground to fill this difference, a balanced match can be achieved. If the hardness is too high, diarrhea is often caused, and the taste is heavy and bitter. Therefore, it is preferable to set the hardness to 200 to 250 as a hardness that balances deliciousness and tenderness to the stomach. Also, compared to other products of the same hardness,
Chlorine ion, sodium ion, and potassium ion are properly removed, making it a product that is very easy to drink and is gentle on the body. The concentrated deep water was separated by an electrodialysis device using an ion exchange membrane having excellent monovalent ion selectivity to obtain a mineral component from which monovalent elements were removed.

【図面の簡単な説明】[Brief description of drawings]

【図1】海洋深層水(日本海固有冷水)の分離例を示す
概略ブロック線図である。
FIG. 1 is a schematic block diagram showing an example of separation of deep sea water (cool water unique to the Sea of Japan).

【図2】本発明による機能性商品群の概略分類図であ
る。
FIG. 2 is a schematic classification diagram of a functional product group according to the present invention.

【図3】機能性商品の具体的分類図である。FIG. 3 is a specific classification diagram of functional products.

【図4】深層水のL−NAME誘発高血圧ラットに及ぼ
す影響の試験方法を示す説明図である。
FIG. 4 is an explanatory view showing a test method for the effect of deep water on L-NAME-induced hypertensive rats.

【図5】NO合成阻害薬、L−NAMEの血圧上昇メカ
ニズムを示す説明図である。
FIG. 5 is an explanatory diagram showing the blood pressure elevation mechanism of NO synthesis inhibitor, L-NAME.

【図6】深層水のL−NAME誘発高血圧ラットにおけ
る体重推移に及ぼす影響を示す計測図である。
FIG. 6 is a measurement diagram showing the influence of deep water on the body weight transition in L-NAME-induced hypertensive rats.

【図7】図6の図表である。FIG. 7 is a chart of FIG.

【図8】L−NAME誘発高血圧ラットにおける血圧に
及ぼす影響を示す計測図である。
FIG. 8 is a measurement diagram showing the effect on blood pressure in L-NAME-induced hypertensive rats.

【図9】図8の図表である。9 is a chart of FIG. 8. FIG.

【図10】L−NAME誘発高血圧ラットにおける心拍
数に及ぼす影響を示す計測図である。
FIG. 10 is a measurement diagram showing the influence on the heart rate in L-NAME-induced hypertensive rats.

【図11】L−NAME誘発高血圧ラットにおける血流
量に及ぼす影響を示す説明図である。
FIG. 11 is an explanatory diagram showing the effect on blood flow in L-NAME-induced hypertensive rats.

【図12】深層水のマウスIgE抗体生産に及ぼす影響
の試験方法を示す説明図である。
FIG. 12 is an explanatory view showing a method for testing the influence of deep layer water on mouse IgE antibody production.

【図13】マウスIgE(免疫グロブリンE)抗体生産
の性質を示す説明図である。
FIG. 13 is an explanatory diagram showing the properties of mouse IgE (immunoglobulin E) antibody production.

【図14】試験郡におけるマウスIgE抗体価を示す説
明図である。
FIG. 14 is an explanatory diagram showing mouse IgE antibody titers in a test group.

【図15】深層水のマウスIgE抗体生産に及ぼす影響
を示す説明図である。
FIG. 15 is an explanatory diagram showing the influence of deep layer water on mouse IgE antibody production.

【図16】深層水のマウスIgE抗体生産における体重
の推移を示す計測図である。
FIG. 16 is a measurement diagram showing changes in body weight during production of deep-water mouse IgE antibody.

【図17】図16の図表である。FIG. 17 is a chart of FIG. 16.

【図18】深層水の実験的生活習慣病モデルに及ぼす影
響の試験方法を示す説明図である。
FIG. 18 is an explanatory diagram showing a test method for the effect of deep water on an experimental lifestyle-related disease model.

【図19】実験的生活習慣病モデルを示す説明図であ
る。
FIG. 19 is an explanatory diagram showing an experimental lifestyle-related disease model.

【図20】生活習慣病モデルにおける深層水の体重に及
ぼす影響を示す説明図である。
FIG. 20 is an explanatory diagram showing the effect of deep water on the body weight in a lifestyle-related disease model.

【図21】生活習慣病モデルにおける深層水の血糖に及
ぼす影響を示す説明図である。
FIG. 21 is an explanatory diagram showing the effect of deep water on blood glucose in a lifestyle-related disease model.

【図22】生活習慣病モデルにおける総コレストロール
に及ぼす影響を示す説明図である。
FIG. 22 is an explanatory diagram showing the effect on total cholesterol in a lifestyle-related disease model.

【図23】生活習慣病モデルにおけるトリグリセリドに
及ぼす影響を示す説明図である。
FIG. 23 is an explanatory diagram showing effects on triglycerides in a lifestyle-related disease model.

【図24】生活習慣病モデルにおける血小板凝集能に及
ぼす影響を示す説明図である。
FIG. 24 is an explanatory diagram showing the effect on platelet aggregation in a lifestyle-related disease model.

【図25】日本海固有冷水(富山湾深層水)と、その分
離後における元素含有状態を示す元素分析図である。
FIG. 25 is an elemental analysis diagram showing the cold water peculiar to the Sea of Japan (Toyama Bay deep water) and the element-containing state after the separation.

【図26】日本海固有冷水から分離した淡水、濃縮深層
水、濃縮ミネラル液、濃縮塩水におけるイオン含有量図
である。
FIG. 26 is an ion content diagram of fresh water, concentrated deep water, concentrated mineral liquid, and concentrated salt water separated from cold water peculiar to the Sea of Japan.

【図27】L−NAME誘発高血圧ラットに対する効果
を示す説明図である。
FIG. 27 is an explanatory diagram showing the effect on L-NAME-induced hypertensive rats.

【図28】マウスIgE抗体生産に対する効果を示す説
明図である。
FIG. 28 is an explanatory diagram showing the effect on mouse IgE antibody production.

【図29】生活習慣病モデルラットに対する効果を示す
説明図である。
FIG. 29 is an explanatory diagram showing the effect on a lifestyle-related disease model rat.

【図30】深層水の効力を裏付けるまとめ図である。FIG. 30 is a summary diagram supporting the efficacy of deep water.

【符号の説明】[Explanation of symbols]

1 一次電気透析装置 2 二次電気透析装置 12,13 イオン交換膜 A 海洋深層水(日本海固有冷水) B 淡水(脱塩水) C 濃縮深層水 D 濃縮ミネラル液 E 濃縮塩水 1 Primary electrodialysis device 2 Secondary electrodialysis equipment 12,13 Ion exchange membrane A Deep sea water (Cold water unique to the Sea of Japan) B Fresh water (demineralized water) C concentrated deep water D concentrated mineral liquid E concentrated salt water

─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───

【手続補正書】[Procedure amendment]

【提出日】平成13年10月17日(2001.10.
17)
[Submission date] October 17, 2001 (2001.10.
17)

【手続補正1】[Procedure Amendment 1]

【補正対象書類名】図面[Document name to be corrected] Drawing

【補正対象項目名】図17[Name of item to be corrected] Fig. 17

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【図17】 FIG. 17

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 33/00 A61P 3/00 A61P 3/00 9/00 9/00 9/12 9/12 37/08 37/08 A23L 2/00 F Fターム(参考) 4B017 LC03 LK02 LP02 LP18 4B018 LB08 LE05 MD01 ME04 ME07 MF01 MF06 4C083 AA021 AA022 AB00 CC01 CC25 DD27 EE11 EE42 4C086 AA01 AA02 HA00 MA01 MA04 MA17 NA14 ZA42 ZB13 ZC21 4C087 AA01 AA02 BA10 MA17 NA14 ZA42 ZB13 ZC21 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 33/00 A61P 3/00 A61P 3/00 9/00 9/00 9/12 9/12 37/08 37/08 A23L 2/00 FF term (reference) 4B017 LC03 LK02 LP02 LP18 4B018 LB08 LE05 MD01 ME04 ME07 MF01 MF06 4C083 AA021 AA022 AB00 CC01 CC25 DD27 EE11 EE42 4C086 AA01 AA02 HA00 MA01 A04 A10 A02 A01 A04 ZB17A02 MA17 NA14 ZA42 ZB13 ZC21

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 海洋深層水より分離したミネラル濃縮液
の機能性を利用したことを特徴とする機能性商品。
1. A functional product characterized by utilizing the functionality of a mineral concentrated liquid separated from deep sea water.
【請求項2】 ミネラル濃縮液の機能性の内、主に血圧
の安定に寄与する機能性を利用したことを特徴とする請
求項1記載の機能性商品。
2. The functional product according to claim 1, wherein among the functional properties of the mineral concentrate, the functional properties mainly contributing to the stabilization of blood pressure are utilized.
【請求項3】 ミネラル濃縮液の機能性の内、主にアレ
ルギー体質の改善に寄与する機能性を利用したことを特
徴とする請求項1記載の機能性商品。
3. The functional product according to claim 1, wherein among the functional properties of the concentrated mineral liquid, the functional properties mainly contributing to improvement of allergic constitution are utilized.
【請求項4】 ミネラル濃縮液の機能性の内、主に生活
習慣病の改善に寄与する機能性を利用したことを特徴と
する請求項1記載の機能性商品。
4. The functional product according to claim 1, wherein among the functional properties of the concentrated mineral liquid, the functional properties mainly contributing to the improvement of lifestyle-related diseases are utilized.
JP2001254117A 2001-08-24 2001-08-24 Functional goods using concentrated mineral solution obtained from deep sea water by separation Pending JP2003063969A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001254117A JP2003063969A (en) 2001-08-24 2001-08-24 Functional goods using concentrated mineral solution obtained from deep sea water by separation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001254117A JP2003063969A (en) 2001-08-24 2001-08-24 Functional goods using concentrated mineral solution obtained from deep sea water by separation

Publications (2)

Publication Number Publication Date
JP2003063969A true JP2003063969A (en) 2003-03-05
JP2003063969A5 JP2003063969A5 (en) 2008-09-18

Family

ID=19082320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001254117A Pending JP2003063969A (en) 2001-08-24 2001-08-24 Functional goods using concentrated mineral solution obtained from deep sea water by separation

Country Status (1)

Country Link
JP (1) JP2003063969A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030680A1 (en) * 2002-10-01 2004-04-15 Ja Lim Pharmaceutical composition comprising bando deep ocean water of the concentrate thereof for treatment and prevention of liver disease
WO2004030679A1 (en) * 2002-10-01 2004-04-15 Ja Lim Pharmaceutical composition comprising bando deep ocean water or the concentrate thereof having cholesterol lowering activity
KR20050014254A (en) * 2003-07-30 2005-02-07 임자 Pharmaceutical composition comprising Bando Deep Ocean Water or the concentrate thereof having anti-cancer activity
WO2005039601A1 (en) * 2003-10-27 2005-05-06 Yoshinobu Kozuka Anticancer drug from deep sea water
WO2005107775A1 (en) * 2004-05-07 2005-11-17 Suntory Limited Composition having effect of modulating autonomic nerves and method of using the same
JP2006104122A (en) * 2004-10-05 2006-04-20 Goshu Yakuhin Kk Bathing agent
JP2006130462A (en) * 2004-11-09 2006-05-25 Goshu Yakuhin Kk Functionalized water and production method therefor
JP2007084517A (en) * 2005-09-26 2007-04-05 Kochi Univ Method for controlling proliferation/motility of helicobacter pylori strain
JP2007291080A (en) * 2006-03-27 2007-11-08 Kochi Univ Functional material originating from ocean deep water, and use thereof
JP2007295881A (en) * 2006-05-02 2007-11-15 Ako Kasei Co Ltd Method for preparing supplement based on customer data
KR101003856B1 (en) * 2008-05-16 2010-12-23 동국대학교 경주캠퍼스 산학협력단 Deep seawater and its uses
JP2011001331A (en) * 2009-06-22 2011-01-06 Goshu Yakuhin Kk DEEP SEA WATER-ORIGINATED COMPOSITION CONTAINING γ-AMINOBUTYRIC ACID, AND METHOD FOR PRODUCING THE SAME
JP2013028583A (en) * 2011-06-22 2013-02-07 Kazunori Maeda Washing liquid for nasal cavity and throat
WO2014188450A1 (en) * 2013-05-23 2014-11-27 Council Of Scientific & Industrial Research Improved process to retain nutritious constituents in potable water obtained through desalination
WO2016068615A1 (en) * 2014-10-29 2016-05-06 주식회사 아리바이오 Composition, containing high-hardness mineral water prepared from salty underground water or deep-sea water, for preventing or alleviating decrease in blood pressure or symptoms related thereto
EP2912956A4 (en) * 2012-10-24 2016-07-27 Aribio Inc Composition for preventing, alleviating or treating constipation, containing high hardness mineral water prepared from deep ocean water or desalinated groundwater
EP3130232A4 (en) * 2014-03-31 2017-11-08 Aribio Inc. Functional beverage including high hardness mineral water produced from salty underground water or deep seawater

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10120578A (en) * 1996-10-24 1998-05-12 Takeshi Ogura Therapeutic and/or preventing agent comprising marine mineral component
JPH114672A (en) * 1997-06-16 1999-01-12 Furuuchikamejirou Shoten Kk Health beverage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10120578A (en) * 1996-10-24 1998-05-12 Takeshi Ogura Therapeutic and/or preventing agent comprising marine mineral component
JPH114672A (en) * 1997-06-16 1999-01-12 Furuuchikamejirou Shoten Kk Health beverage

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030680A1 (en) * 2002-10-01 2004-04-15 Ja Lim Pharmaceutical composition comprising bando deep ocean water of the concentrate thereof for treatment and prevention of liver disease
WO2004030679A1 (en) * 2002-10-01 2004-04-15 Ja Lim Pharmaceutical composition comprising bando deep ocean water or the concentrate thereof having cholesterol lowering activity
KR20050014254A (en) * 2003-07-30 2005-02-07 임자 Pharmaceutical composition comprising Bando Deep Ocean Water or the concentrate thereof having anti-cancer activity
WO2005039601A1 (en) * 2003-10-27 2005-05-06 Yoshinobu Kozuka Anticancer drug from deep sea water
WO2005107775A1 (en) * 2004-05-07 2005-11-17 Suntory Limited Composition having effect of modulating autonomic nerves and method of using the same
JP4614123B2 (en) * 2004-10-05 2011-01-19 五洲薬品株式会社 Bath preparation
JP2006104122A (en) * 2004-10-05 2006-04-20 Goshu Yakuhin Kk Bathing agent
JP2006130462A (en) * 2004-11-09 2006-05-25 Goshu Yakuhin Kk Functionalized water and production method therefor
JP4693390B2 (en) * 2004-11-09 2011-06-01 五洲薬品株式会社 Functional addition water and its production method
JP2007084517A (en) * 2005-09-26 2007-04-05 Kochi Univ Method for controlling proliferation/motility of helicobacter pylori strain
JP2007291080A (en) * 2006-03-27 2007-11-08 Kochi Univ Functional material originating from ocean deep water, and use thereof
JP2007295881A (en) * 2006-05-02 2007-11-15 Ako Kasei Co Ltd Method for preparing supplement based on customer data
KR101003856B1 (en) * 2008-05-16 2010-12-23 동국대학교 경주캠퍼스 산학협력단 Deep seawater and its uses
JP2011001331A (en) * 2009-06-22 2011-01-06 Goshu Yakuhin Kk DEEP SEA WATER-ORIGINATED COMPOSITION CONTAINING γ-AMINOBUTYRIC ACID, AND METHOD FOR PRODUCING THE SAME
JP2013028583A (en) * 2011-06-22 2013-02-07 Kazunori Maeda Washing liquid for nasal cavity and throat
EP2912956A4 (en) * 2012-10-24 2016-07-27 Aribio Inc Composition for preventing, alleviating or treating constipation, containing high hardness mineral water prepared from deep ocean water or desalinated groundwater
WO2014188450A1 (en) * 2013-05-23 2014-11-27 Council Of Scientific & Industrial Research Improved process to retain nutritious constituents in potable water obtained through desalination
EP3130232A4 (en) * 2014-03-31 2017-11-08 Aribio Inc. Functional beverage including high hardness mineral water produced from salty underground water or deep seawater
WO2016068615A1 (en) * 2014-10-29 2016-05-06 주식회사 아리바이오 Composition, containing high-hardness mineral water prepared from salty underground water or deep-sea water, for preventing or alleviating decrease in blood pressure or symptoms related thereto

Similar Documents

Publication Publication Date Title
JP2003063969A (en) Functional goods using concentrated mineral solution obtained from deep sea water by separation
JP5312325B2 (en) Soft drink and method for producing the same
AU764290B2 (en) Drinks with the use of seawater and process for producing the same
CN100355666C (en) Mineral composition using marine water
JP2002292371A (en) Fresh water obtained from deep sea water, concentrated deep sea water, mineral concentrate, concentrated salt water, bittern, and specifyed salt
JP3545692B2 (en) Sports drinks using deep ocean water
JPH05219921A (en) Soft drink utilizing marine deep water and its production
KR101271925B1 (en) Mineral Alkaline Water
JP2018014978A (en) As mineral component magnesium and calcium-containing soft drink
JP2005348626A (en) Healthy drinking water and method for producing the same
JP4045060B2 (en) Deep water beverage containing mineral components derived from mineral spring water
JP2000295974A (en) Beverage using seawater and its production
CN106954771A (en) Pollen health beverage
JP4045061B2 (en) Mineral water beverage containing mineral components derived from deep water
JP4607164B2 (en) Beverage production method
JP2002192169A (en) Beverage using seawater as raw material and raw material water thereof
TWI466832B (en) Manufacturing method of deep-sea active concentrated solution
JP2007166990A (en) Deep seawater using method
JP4754806B2 (en) Barley tea drink with blood flow improving effect by adjusting the amount of magnesium and potassium
US20130122140A1 (en) Alkaline Mineral Booster With Antioxidants
JP2002017315A (en) Beverage using oceanic deep water
JP2001103945A (en) Production of low potassium juice having improved flavor
KR20120091977A (en) Alkaline mineral booster with antioxidants
JP2001136942A (en) Beverage containing deep water
JP4536480B2 (en) Beverage manufacturing method using seawater

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20111012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111115